Resources>Antibody Industry Trends>Biointron Insights: Antibody Industry Report (Q1 2025 Insights, Trends & Analysis)

Biointron Insights: Antibody Industry Report (Q1 2025 Insights, Trends & Analysis)

Biointron 2025-03-31
Biointron Insights
Biointron Insights: Antibody Industry Report (Q1 2025 Insights, Trends & Analysis)

Biointron’s Q1 2025 annual antibody report aims to explore the events and trends of the biopharmaceutical industry in 2025 (January, February, March). This quarter, 6 novel monoclonal antibody drugs have been approved by at least one regulatory agency around the world: three from China, two from the EU, and one from Australia:

  1. Vilobelimab (Gohibic)

  2. Garadacimab (Andembry)

  3. Finotonlimab (新替妥)

  4. Siltartoxatug (Sintetol)

  5. Sipavibart (Kavigale)

  6. Teprotumumab N01 (Sycume)

Q1 2025 saw several large collaborations and acquisitions of up to USD$3.1 billion in value. The majority of collaborative efforts focused on developing novel platforms such as bispecific antibody and ADC engineering.

Gain exclusive insights into current trends such as:

  • 6 novel antibody drugs approved for the first time in Q1

  • Top 10 antibody drug deals, including collaborations, M&As, and funding rounds of up to US$3.1B

  • Novel platforms such as bispecific antibody and ADC engineering

  • Recent research into obesity and COVID-19 treatments

  • A list of antibody drugs in regulatory review to keep an eye out for in Q2 2025


Please fill in the form below to download


Recommended Articles
Biointron Insights: Antibody Industry Trends (Q3 2026 Insights, Trends & Analysis)

Biointron's Q3 2026 Antibody Industry Trends report aims to explore the events a……

Sep 30, 2026
November 2026: Bispecifics x AI: From Design to Clinic

Bispecific antibodies (BsAbs) can bind two different antigens simultaneously, of……

Nov 09, 2026
Week 1, November 2026: VNAR vs. VHH: What's the Difference Between Shark and Camelid Single-Domain Antibodies?

When we think of antibodies, sharks and alpacas probably aren't the first an……

Nov 03, 2026
Week 3, October 2026: The Evolving Role of Biomarkers in Antibody-Based Cancer Therapies

Antibody-based cancer therapies have expanded treatment options across multiple ……

Oct 21, 2026

Our website uses cookies to improve your experience. Read our Privacy Policy to find out more.